138 research outputs found
Recommended from our members
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
BackgroundNovel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument's ability to detect clinically meaningful treatment benefit for this context of use.MethodsOur mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30.ResultsUnique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact) were selected for the MDS/AML/CMML context.ConclusionSupplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning
Limitaciones de la Ley n.° 29904 en saneamiento físico legal de predios que comprenden proyectos de instalación de nodos de banda ancha
El trabajo de investigación tuvo como objetivo general analizar la Ley n.° 29904 que
limita el saneamiento físico legal de predios destinados en la instalación de nodos
de banda. En ese sentido, se aplicó un enfoque cualitativo de tipo básico con un
diseño fenomenológico, asimismo, se utilizó como técnica de investigación la
entrevista, con el instrumento guía de entrevista, donde los participantes fueron 5
abogados, con más de 6 años de experiencia y con especialidad en
Telecomunicaciones, Saneamiento Físico Legal, Derecho Administrativo y Gestión
Pública.
Por consiguiente, se llegó a la conclusión que se debe establecer en la Ley
n.° 29904, los lineamientos necesarios para facilitar el saneamiento físico legal de
estos predios, marcos de comunicación, de acuerdo a las dimensiones,
características, porcentajes de estos terrenos donde se instalará las redes de
conectividad, entonces, el poder tener un marco regulatorio adecuado permitiría
que se viabilice la construcción de nodos, llenado así esos vacíos legales
preexistente en dicha Ley, en beneficio de los usuarios para que puedan acceder a
la información con mayor velocidad y permanencia
684 The <i>in vitro</i> effects of 5-Azacitidine on the immunophenotype of monocyte-derived dendritic cells from patients with higher-risk myelodysplastic syndromes
BackgroundMyelodysplastic syndromes (MDS) are the most common acquired cause of bone marrow failure. Though DNA hypomethylating agents (HMAs) such as 5-Azacitidine (5-Aza) may increase survival of patients with higher-risk MDS, their mechanistic effects on hematopoiesis and immune cell function remain unclear. Using whole exome sequencing analysis, we previously identified MDS-related mutations within monocyte-derived dendritic cells (moDCs) from patients with higher-risk MDS. Here we examine the effect of 5-Aza on the phenotype of moDCs from the same cohort of patients with higher-risk MDS.MethodsPurified CD14+ cells were magnetically isolated from peripheral blood mononuclear cells from 6 patients with IPSS-R Intermediate/High/Very High-risk MDS (herein collectively referred to as higher-risk MDS). Cells were cultured in complete medium with IL-4 (800 U/mL) and GM-CSF (1200 U/mL) for 5 days. Freshly prepared 5-Aza or dimethylsulfoxide (DMSO) vehicle was added to cultures every 24 hours for a total of three 1 μM doses starting on Day 1. Immature moDCs were then stimulated with poly(I:C) (20 ng/mL), IL-1β (25 ng/mL), IFN-α (3000 U/mL), IFN-γ (1000 U/mL), and TNF-α (50 ng/mL) for 48 hours to generate moDCs. Flow cytometry analyses were performed with Guava easyCyte 8HT before and after addition of maturation cocktail.ResultsBased on trypan blue staining, in vitro addition of 5-Aza to CD14+ cells from 6 patients with higher-risk MDS did not result in a significant reduction in the percentage of cell survival on Day 5 and Day 7 in culture (figure 1a, p=0.8765 and p=0.7109, respectively). Treatment with 5-Aza significantly reduced the percentage of CD14-CD209+ moDCs on Day 7 following the addition of maturation cocktail (figure 1b, p<0.0001). Flow cytometry assessment showed comparable expression of common maturation and co-stimulatory markers such as CD80, CD83, CD86, HLA-DR, CD209, CD141, CD40, and CCR7 between 5-Aza and DMSO-treated immature moDCs on Day 5 (figure 1c). Similarly, 5-Aza treatment had no significant effect on marker expression on mature moDCs generated with maturation cocktail on Day 7.ConclusionsThere was no significant difference in maturation and co-stimulatory marker expression of immature and mature moDCs from patients with higher-risk MDS following in vitro treatment with 5-Aza. Though recent studies have identified important immunoregulatory effects of 5-Aza, functional changes that may occur within the dendritic cell population are not fully understood. Further studies are planned, including cytokine analyses and transcriptome sequencing of mature moDCs, and may help elucidate the immunological mechanisms underlying the therapeutic effects of 5-Aza in patients with higher-risk MDS.Ethics ApprovalThe study is being conducted as per the Declaration of Helsinki and was approved by the University of California San Diego Institutional Review Board (#161345) and registered with ClinicalTrials.gov (NCT02667093). All patients were provided written informed consent.Abstract 684 Figure 15-Aza and DMSO vehicle-treated moDCs from patients with higher-risk MDS were evaluated for phenotypic markers before and after stimulation with maturation cocktail. Purified CD14+ cells were magnetically isolated from PBMC from 6 higher-risk MDS patients and cultured with IL-4 and GM-CSF for 5 days followed by addition of poly(I:C), IL-1β, IFN-α, IFN-γ, and TNF-α for 48 hours at 37°C in a 5% CO2 incubator. Freshly prepared 5-Aza or DMSO vehicle was added to cultures every 24 hours for a total of three 1 μM doses starting on Day 1. (A) Cultured cells were stained with trypan blue to determine the percentage of cell survival on Day 5 and Day 7 in culture. (B) Treatment with 5-Aza significantly reduced the percentage of CD14-CD209+ moDCs on Day 7 following addition of maturation cocktail (p<0.0001). (C) The percentage of CD14-CD83+ cells is comparable between 5-Aza and vehicle-treated immature moDCs on Day 5 and mature moDCs on Day 7 (p=0.2434 and p=0.5846, respectively). (D) Cultured cells were stained with fluorochrome-conjugated antibodies to determine the expression of common maturation and co-stimulatory markers using flow cytometry. Cells were gated on CD14-CD11c+ to distinguish moDCs, and scatterplots represent the geometric mean fluorescence intensity (gMFI) of marker expression pre- and post-maturation. Individual dots represent one of three experimental replicates performed for the 6 higher-risk MDS patient samples. Each dot is labeled by MDS patient sample. Statistical analysis was performed by Welch's t-test using GraphPad Prism
Boletín NUESTRA AMÉRICA XXI - Desafíos y alternativas, num.7, mayo 2017
Una excelente iniciativa del Grupo de Trabajo Crisis y economía mundial, coordinado por María Josefina Morales y Gabriela Roffinelli
A low-mass triple system with a wide L/T transition brown dwarf component: NLTT 51469AB/SDSS 2131-0119
We demonstrate that the previously identified L/T transition brown dwarf SDSS J213154.43-011939.3 (SDSS 2131-0119) is a widely separated (82 ''.3, similar to 3830 au) common proper motion companion to the low-mass star NLTT 51469, which we reveal to be a close binary itself, separated by 0 ''.64 +/- 0 ''.01 (similar to 30 au). We find the proper motion of SDSS 2131-0119 of mu(alpha) cos delta = -100 +/- 20 mas yr(-1) and mu(delta) = -230 +/- 20 mas yr(-1) consistent with the proper motion of the primary provided by Gaia DR2: mu(alpha) cos delta = -95.49 +/- 0.96 mas yr(-1) and mu(delta) = -239.38 +/- 0.96 mas yr(-1). Based on optical and near-infrared spectroscopy, we classify the primary NLTT 51469A as an M3 +/- 1 dwarf, estimate photometrically the spectral type of its close companion NLTT 51469B at similar to M6, and confirm the spectral type of the brown dwarf to be L9 +/- 1. Using radial velocity, proper motion, and parallax, we derived the UVW Galactic space velocities of NLTT 51469A, showing that the system does not belong to any known young stellar moving group. The high V, W velocities, lack of a 670.8 nm Li I absorption line, and absence of H alpha emission, detected X-rays, or UV excess, indicate that the system is likely a member of the thin disc population and is older than 1 Gyr. For the parallactic distance of 46.6 +/- 1.6 pc from Gaia DR2, we determined luminosities of -1.50(-0.04)(+0.02) and -4.4 +/- 0.1 dex of the M3 and L9, respectively. Considering the spectrophotometric estimation, which yields a slightly lower distance of 34(-13)(+10) pc, the obtained luminosities are -1.78(-0.04)(+0.02) and -4.7(-0.5)(+0.3) dex. We also estimated their effective temperatures and masses, and obtained 3410(-210)(+140) K and 0.42 +/- 0.02 M-circle dot for the primary, and 1400-1650K and 0.05-0.07 M-circle dot for the wide companion. For the similar to M6 component, we estimated T-eff = 2850 +/- 200 K and m = 0.10(-0.01)(+0.06) M-circle dot.BG acknowledges support from the CONICYT through FONDECYT Postdoctoral Fellowship grant no. 3170513. This work is partly financed by the Spanish Ministry of Economy and Competitiveness through the project AYA2016-79425-C3-2-P. NL and VJSB acknowledge support from the SpanishMinistry of Economy and Competitivity through the project AYA2015-69350-C3-2-P. AP acknowledges support from the Spanish Ministry of Economy and Competitivity through the project AYA2015-69350-C3-3-P. Based on observations obtained as part of the VHS, ESO programme, 179.A-2010 (PI: McMahon). Based on observations collected at the European Organisation for Astronomical Research in the Southern hemisphere under ESO programme 092.C-0874(B). Based on observations made with the NOT, operated by the Nordic Optical Telescope Scientific Association at the Observatorio del Roque de los Muchachos, La Palma, Spain, of the Instituto de Astrofisica de Canarias. This paper includes data obtained using the 6.5 m Magellan Clay Telescope at Las Campanas Observatory, Chile. This publication makes use of data products from the Two Micron All Sky Survey, which is a joint project of the University of Massachusetts and the Infrared Processing and Analysis Center/California Institute of Technology, funded by the National Aeronautics and Space Administration and the National Science Foundation. This publication makes use of data products from the Wide-field Infrared Survey Explorer, which is a joint project of the University of California, Los Angeles, and the Jet Propulsion Laboratory/California Institute of Technology, funded by the National Aeronautics and Space Administration. This work has made use of data from the European Space Agency (ESA) mission Gaia (https://www.cosmos.esa.int/gaia), processed by the Gaia Data Processing and Analysis Consortium (DPAC, https://www.cosmos.esa.int/web/gaia/dpac/consortium).Funding for the DPAC has been provided by national institutions, in particular the institutions participating in the Gaia Multilateral Agreement. This research has made use of NASA's Astrophysics Data System. We have made use of the ROSAT Data Archive of the Max-Planck-Institut fur extraterrestrische Physik (MPE) at Garching, Germany. This research has made use of theWashington Double Star Catalog maintained at the U.S. Naval Observatory
Memoria del XVIII Seminario de Economía Mexicana. La economía en el Segundo año del gobierno de Fox
Fundado por el maestro José Luis Ceceña Gámez en 1983, el Seminario de Economía
Mexicana se ha convertido en un importante espacio de reflexión económica para los
investigadores de la UNAM y de otras instituciones, a través de diecisiete reuniones anuales
orientadas a examinar temas relevantes de —y para— la economía mexicana. En su
dieciochoava edición, que ahora iniciamos, el Seminario tendrá como tema general: La
economía mexicana durante el segundo año del gobierno de Fox. Evaluación y alternativas.
Será un ejercicio académico orientado a examinar el estado en que se encuentra la economía
mexicana, las condiciones del entorno económico internacional, las políticas económicas
desplegadas por el gobierno del presidente Fox, y las propuestas viables de política económica
alternativa capaces de superar el pobre y errático desempeño mostrado por la economía
mexicana durante las dos últimas décadas
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promise of improving patients' health‐related quality of life (HRQoL). Within this rapidly evolving landscape, the inclusion of HRQoL and other patient‐reported outcomes (PROs) is critical to inform the benefit/risk assessment of new therapies or to assess whether patients live longer and better, for what will likely remain a largely incurable disease. We provide practical considerations to support investigators in generating high‐quality PRO data in future MDS trials. We first describe several challenges that are to be thoughtfully considered when designing an MDS‐focused clinical trial with a PRO endpoint. We then discuss aspects related to the design of the study, including PRO assessment strategies. We also discuss statistical approaches illustrating the potential value of time‐to‐event analyses and their implications within the estimand framework. Finally, based on a literature review of MDS randomized controlled trials with a PRO endpoint, we note the PRO items that deserve special attention when reporting future MDS trial results. We hope these practical considerations will facilitate the generation of rigorous PRO data that can robustly inform MDS patient care and support treatment decision‐making for this patient population
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
View full abstracthttps://openworks.mdanderson.org/leading-edge/1025/thumbnail.jp
- …